Debt-to-equity of AN2 Therapeutics, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
AN2 Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2022 to 30 Sep 2025.
  • AN2 Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 11%, a 6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

AN2 Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 11% +0.64% +6% 30 Sep 2025
Q2 2025 11% +0.8% +7.6% 30 Jun 2025
Q1 2025 11% +0.28% +2.6% 31 Mar 2025
Q4 2024 11% -0.36% -3.2% 31 Dec 2024
Q3 2024 11% +0.33% +3.2% 30 Sep 2024
Q2 2024 11% +2.1% +24% 30 Jun 2024
Q1 2024 11% +4.9% +80% 31 Mar 2024
Q4 2023 11% +6.4% +132% 31 Dec 2023
Q3 2023 10% +4.4% +75% 30 Sep 2023
Q2 2023 8.4% 30 Jun 2023
Q1 2023 6.1% 31 Mar 2023
Q4 2022 4.8% 31 Dec 2022
Q3 2022 5.9% 30 Sep 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.